Developer docs
API playgroundTry for free, no card

Search company profiles

limula biotech

Full company profile

uuid02m9k94

Namestring
limula biotech
Legal namestring
Limula SA
Company typeenum
Private
Founded yearint
2020
Descriptiontext

Limula Biotech (legal entity: Limula SA) is a Swiss biotechnology company headquartered at Biopôle StartLab in Lausanne, Switzerland, that develops automated hardware platforms for the manufacturing of personalized cell and gene therapies. The company's defining technical innovation is a proprietary platform that combines a bioreactor and a centrifuge into a single closed device, enabled by in-situ centrifugation — a capability that allows complex cell processing steps to be sequenced in one container without human intervention. Limula's commercial product portfolio consists of two offerings: LimONE, an automated all-in-one closed system for cell processing, and LimGROW, a scalable bioreactor supporting both process development (scale-down) and commercial manufacturing (scale-up/scale-out).

The platform is designed to serve four customer segments: cell therapy manufacturers producing autologous therapies (T cells, hematopoietic stem cells), allogeneic cell therapy developers, contract development and manufacturing organizations (CDMOs), and pharmaceutical companies. Limula pursues a partnership-driven, enterprise sales motion — offering Early Access Programs to selected partners with compelling use cases — and engages stakeholders across the broader Cell & Gene Therapy value chain. Revenue mechanics are anchored on hardware/platform sales (LimONE, LimGROW), recurring single-use consumables, integrated software for process control and user experience, and collaborative partnership agreements, with quote-based enterprise pricing and multi-year contracts. The company maintains no publicly disclosed pricing, revenue figures, or funding rounds.

Limula markets through content (website, downloadable white papers, posters, application notes), conference participation (ISCT, ESGCT, Basel Cell Symposium, AdvT), a quarterly newsletter, and direct partner outreach. The company has assembled an ecosystem of approximately 26 supporting partner organizations since 2020 and is actively hiring engineers and biologists while soliciting new investors. No management team, board, funding history, revenue, headcount, or patents are disclosed in available sources, and the company is classified as pre-commercial or early commercial.

Short descriptiontext

Limula Biotech is a Swiss company that builds automated, closed hardware platforms combining a bioreactor and centrifuge (LimONE and LimGROW) for manufacturing personalized cell and gene therapies. It sells to cell therapy manufacturers, allogeneic developers, CDMOs, and pharmaceutical companies via an early-access enterprise model.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersEpalinges, Switzerland
HQ citystring
Epalinges
HQ countrystring
Switzerland
HQ regionstring
Europe
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
cell therapy manufacturing, bioreactor technology, gene therapy automation, cell processing platforms, biopharmaceutical equipment
Industry3 codes
PRIMARYHLAAABAG
Cell Therapy Manufacturing Platforms & Automation (closed systems, bioreactors, fill-finish)
Healthcare & Life Sciences/Biotechnology & Biologics/Cell Therapy (autologous/allogeneic)
SECONDARYHLAGAGAA
Cell Therapy CDMO (Autologous/Allogeneic Manufacturing)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Biopharma Manufacturing Services (Biologics/Cell & Gene)
SECONDARYHLAGAGAG
Fill-Finish & Aseptic Drug Product Manufacturing (Biologics/ATMP)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Biopharma Manufacturing Services (Biologics/Cell & Gene)
NAICS code1 code
  • Medical Equipment and Supplies Manufacturing3391
SIC code1 code
  • Surgical & Medical Instruments & Apparatus3841
Product category
Cell Therapy Manufacturing Equipment
Social media profiles2 records
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model4 records
1Hardware/Platform Sales
TypeHardware Sales
Description

Sale of LimOne and LimGROW automated manufacturing platforms combining bioreactor and centrifuge technology for cell and gene therapy production

limula.ch
2Consumables
TypeHardware Sales
Description

Single-use consumables for the closed automated platform, enabling cell processing in a single container

limula.ch
3Software
TypeHardware Sales
Description

Software component integrated into the automated platform for intuitive user experience and process control

limula.ch
4Partnership/Early Access Programs
TypeHardware Sales
Description

Early access to technology offered to selected partners with exciting use cases; collaborative partnerships for technology adoption

limula.ch
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Operations, Supply Chain, Marketing or Sales
Pricing details1 tier
1Quote-based enterprise pricing
ModelOtherBilling cadenceMulti-year contract
Notes

No public pricing available. Early access and partnership programs available for selected partners. Direct contact required for commercial inquiries.

limula.ch
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 2 records shown
1LimOne
Description

Automated closed platform for cell therapy manufacturing combining bioreactor and centrifuge capabilities.

limula.ch
+1 more record
Core offering1 text field

Limula Biotech develops and manufactures automated, all-in-one closed platforms for cell and gene therapy manufacturing. Its proprietary hardware combines a bioreactor and a centrifuge into a single device using in-situ centrifugation, enabling complex cell processing steps to be sequenced in one container without human intervention. The portfolio includes the LimONE automated closed manufacturing platform and the LimGROW scalable bioreactor for cell growth and expansion, sold to cell therapy developers, CDMOs, and pharmaceutical companies.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 5 values shown
  • Low hands-on time compared to existing cell therapy manufacturing solutions
+4 more records
Product overview1 text field

Limula offers a unified platform for cell and gene therapy manufacturing across scales. The portfolio consists of two core products: LimONE, an automated all-in-one closed system combining bioreactor and centrifuge capabilities for cell processing; and LimGROW, a scalable bioreactor for process development and commercial manufacturing. Both products leverage proprietary in-situ centrifugation technology to enable automated, closed, and versatile cell therapy manufacturing with minimal human intervention.

Product and service1 record
1LimONE
Scale indicator1 record

Each record includes

Type, Value, Description, Source

Partnership1 partner
1Various Partner Organizations
Strategic tierCoreTypeOthersAnnounced on2020-01-01
Description

Limula has received support from numerous partner organizations since 2020, though specific partner names are not individually listed in the text. The company logo section displays approximately 26 partner organization logos including StartLab, Biopôle, and various other industry organizations supporting the company's development.

limula.ch
Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Established manufacturer of cell processing instruments, reagents, and closed automation systems (e.g., Prodigy) used by cell therapy developers and CDMOs. Directly comparable to Limula as a hardware-plus-consumables platform for autologous and allogeneic cell therapy manufacturing.

TypeDirect peer
Description

Developer of automated, closed, factory-in-a-box cell therapy manufacturing platforms (Cell Shuttle) targeting pharma and CDMO customers. Closely aligned with Limula's positioning of an end-to-end automated, scalable cell therapy manufacturing solution.

TypeBroad incumbent
Description

Global bioprocessing supplier of bioreactors, single-use systems, and cell therapy workflow tools. Comparable as a broad incumbent providing the equipment ecosystem that cell therapy manufacturers rely on, even if not a single-vessel automated platform like Limula.

TypeBroad incumbent
Description

Global CDMO and bioprocessing technology provider with deep cell and gene therapy manufacturing capabilities. Relevant as both a potential customer (using Limula's platform) and as an incumbent defining current manufacturing standards.

TypeDirect peer
Description

Supplier of cell processing, centrifugation, and blood component technologies including the Quantum and Elutra cell expansion systems. Directly comparable for cell therapy manufacturers seeking closed, automated processing hardware.

TypeBroad incumbent
Description

Major bioprocessing equipment and consumables supplier serving cell and gene therapy manufacturers with bioreactors and process solutions. Comparable as a broad incumbent that Limula's platform would either complement or compete against.

TypeEmerging player
Description

Developer of robotic and automated manufacturing platforms for cell therapies and other advanced biologics. Comparable as a newer entrant pursuing closed, automated cell therapy manufacturing in competition with Limula.

TypeBroad incumbent
Description

Global life sciences leader providing cell therapy manufacturing tools, reagents, and CDMO services through its Patheon and PPD units. Comparable as an incumbent whose cell therapy workflow products overlap with Limula's automation platform.

TypeBroad incumbent
Description

Provider of cell therapy manufacturing solutions, including the Lovo cell processing platform and adjacent bioprocessing products. Comparable as an established supplier of automated cell processing systems to cell therapy developers.

TypeEmerging player
Description

Developer of an automated, closed cell and gene therapy manufacturing platform targeting scalability and process standardization. Comparable as a direct emerging competitor with similar positioning to Limula.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat3 records

Each record includes

Type, Details

Key risks7 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers5 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

limula biotech

Cell Therapy Manufacturing Equipmentlimula-biotech.com

Limula Biotech is a Swiss company that builds automated, closed hardware platforms combining a bioreactor and centrifuge (LimONE and LimGROW) for manufacturing personalized cell and gene therapies. It sells to cell therapy manufacturers, allogeneic developers, CDMOs, and pharmaceutical companies via an early-access enterprise model.

What limula biotech does

Limula Biotech (legal entity: Limula SA) is a Swiss biotechnology company headquartered at Biopôle StartLab in Lausanne, Switzerland, that develops automated hardware platforms for the manufacturing of personalized cell and gene therapies. The company's defining technical innovation is a proprietary platform that combines a bioreactor and a centrifuge into a single closed device, enabled by in-situ centrifugation — a capability that allows complex cell processing steps to be sequenced in one container without human intervention. Limula's commercial product portfolio consists of two offerings: LimONE, an automated all-in-one closed system for cell processing, and LimGROW, a scalable bioreactor supporting both process development (scale-down) and commercial manufacturing (scale-up/scale-out).

The platform is designed to serve four customer segments: cell therapy manufacturers producing autologous therapies (T cells, hematopoietic stem cells), allogeneic cell therapy developers, contract development and manufacturing organizations (CDMOs), and pharmaceutical companies. Limula pursues a partnership-driven, enterprise sales motion — offering Early Access Programs to selected partners with compelling use cases — and engages stakeholders across the broader Cell & Gene Therapy value chain. Revenue mechanics are anchored on hardware/platform sales (LimONE, LimGROW), recurring single-use consumables, integrated software for process control and user experience, and collaborative partnership agreements, with quote-based enterprise pricing and multi-year contracts. The company maintains no publicly disclosed pricing, revenue figures, or funding rounds.

Limula markets through content (website, downloadable white papers, posters, application notes), conference participation (ISCT, ESGCT, Basel Cell Symposium, AdvT), a quarterly newsletter, and direct partner outreach. The company has assembled an ecosystem of approximately 26 supporting partner organizations since 2020 and is actively hiring engineers and biologists while soliciting new investors. No management team, board, funding history, revenue, headcount, or patents are disclosed in available sources, and the company is classified as pre-commercial or early commercial.

limula biotech firmographics

Firmographics
Name
limula biotech
Legal name
Limula SA
Website
https://limula-biotech.com
Company type
Private
Founded year
2020
Operating status
Operating
Headcount range
11–50 employees
Short description
Limula Biotech is a Swiss company that builds automated, closed hardware platforms combining a bioreactor and centrifuge (LimONE and LimGROW) for manufacturing personalized cell and gene therapies. It sells to cell therapy manufacturers, allogeneic developers, CDMOs, and pharmaceutical companies via an early-access enterprise model.
Ownership category
akta.pro rank

limula biotech industry classification

Industry
Product category
Cell Therapy Manufacturing Equipment
NAICS
Medical Equipment and Supplies Manufacturing (3391)
SIC
Surgical & Medical Instruments & Apparatus (3841)
akta.pro industry
PRIMARYHLAAABAG
Cell Therapy Manufacturing Platforms & Automation (closed systems, bioreactors, fill-finish)
Healthcare & Life Sciences/Biotechnology & Biologics/Cell Therapy (autologous/allogeneic)
SECONDARYHLAGAGAA
Cell Therapy CDMO (Autologous/Allogeneic Manufacturing)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Biopharma Manufacturing Services (Biologics/Cell & Gene)
SECONDARYHLAGAGAG
Fill-Finish & Aseptic Drug Product Manufacturing (Biologics/ATMP)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Biopharma Manufacturing Services (Biologics/Cell & Gene)

Keywords

  • Cell therapy manufacturing
  • Bioreactor technology
  • Gene therapy automation
  • Cell processing platforms
  • Biopharmaceutical equipment

Where limula biotech is headquartered

Location

Headquarters

HQ city
Epalinges
HQ country
Switzerland
HQ region
Europe

Offices1 record

Markets served

limula biotech business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Supply Chain, Marketing or Sales

Revenue model

  1. Hardware/Platform Sales: Sale of LimOne and LimGROW automated manufacturing platforms combining bioreactor and centrifuge technology for cell and gene therapy production
  2. Consumables: Single-use consumables for the closed automated platform, enabling cell processing in a single container
  3. Software: Software component integrated into the automated platform for intuitive user experience and process control
  4. Partnership/Early Access Programs: Early access to technology offered to selected partners with exciting use cases; collaborative partnerships for technology adoption

Pricing tiers

ModelBillingPrice
OtherMulti-year contractQuote-based enterprise pricing

Go-to-market motion1 record

Distribution channels3 records

Marketing channels6 records

limula biotech product offering

Product offering

Core offering

Limula Biotech develops and manufactures automated, all-in-one closed platforms for cell and gene therapy manufacturing. Its proprietary hardware combines a bioreactor and a centrifuge into a single device using in-situ centrifugation, enabling complex cell processing steps to be sequenced in one container without human intervention. The portfolio includes the LimONE automated closed manufacturing platform and the LimGROW scalable bioreactor for cell growth and expansion, sold to cell therapy developers, CDMOs, and pharmaceutical companies.

Product overview

Limula offers a unified platform for cell and gene therapy manufacturing across scales. The portfolio consists of two core products: LimONE, an automated all-in-one closed system combining bioreactor and centrifuge capabilities for cell processing; and LimGROW, a scalable bioreactor for process development and commercial manufacturing. Both products leverage proprietary in-situ centrifugation technology to enable automated, closed, and versatile cell therapy manufacturing with minimal human intervention.

Differentiator

Problem solved

Functional benefit

Brands

  • LimOne: Automated closed platform for cell therapy manufacturing combining bioreactor and centrifuge capabilities.
  • LimGROW

Products and services

  • LimONE

Quantifiable outcome

  • Low hands-on time compared to existing cell therapy manufacturing solutions
  • +4 more outcomes

Companies that use limula biotech

Customer profile

Named customers5 records

Segments4 records

Ideal customer profiles3 records

limula biotech technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature5 records

limula biotech partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • Various Partner OrganizationscoreOthers · 1 January 2020Limula has received support from numerous partner organizations since 2020, though specific partner names are not individually listed in the text. The company logo section displays approximately 26 partner organization logos including StartLab, Biopôle, and various other industry organizations supporting the company's development.

Scale indicators1 record

Recent moves6 records

Expansion highlights5 records

limula biotech competitors and assessment

Company assessment

Direct peers

  • Miltenyi Biotec: Established manufacturer of cell processing instruments, reagents, and closed automation systems (e.g., Prodigy) used by cell therapy developers and CDMOs. Directly comparable to Limula as a hardware-plus-consumables platform for autologous and allogeneic cell therapy manufacturing.
  • Cellares: Developer of automated, closed, factory-in-a-box cell therapy manufacturing platforms (Cell Shuttle) targeting pharma and CDMO customers. Closely aligned with Limula's positioning of an end-to-end automated, scalable cell therapy manufacturing solution.
  • Terumo BCT: Supplier of cell processing, centrifugation, and blood component technologies including the Quantum and Elutra cell expansion systems. Directly comparable for cell therapy manufacturers seeking closed, automated processing hardware.

Broad incumbents

  • Cytiva: Global bioprocessing supplier of bioreactors, single-use systems, and cell therapy workflow tools. Comparable as a broad incumbent providing the equipment ecosystem that cell therapy manufacturers rely on, even if not a single-vessel automated platform like Limula.
  • Lonza: Global CDMO and bioprocessing technology provider with deep cell and gene therapy manufacturing capabilities. Relevant as both a potential customer (using Limula's platform) and as an incumbent defining current manufacturing standards.
  • Sartorius: Major bioprocessing equipment and consumables supplier serving cell and gene therapy manufacturers with bioreactors and process solutions. Comparable as a broad incumbent that Limula's platform would either complement or compete against.
  • Thermo Fisher Scientific: Global life sciences leader providing cell therapy manufacturing tools, reagents, and CDMO services through its Patheon and PPD units. Comparable as an incumbent whose cell therapy workflow products overlap with Limula's automation platform.
  • Fresenius Kabi: Provider of cell therapy manufacturing solutions, including the Lovo cell processing platform and adjacent bioprocessing products. Comparable as an established supplier of automated cell processing systems to cell therapy developers.

Emerging players

  • Multiply Labs: Developer of robotic and automated manufacturing platforms for cell therapies and other advanced biologics. Comparable as a newer entrant pursuing closed, automated cell therapy manufacturing in competition with Limula.
  • Ori Biotech: Developer of an automated, closed cell and gene therapy manufacturing platform targeting scalability and process standardization. Comparable as a direct emerging competitor with similar positioning to Limula.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks7 records

Key highlights7 records

Customer concentration

limula biotech social profiles

Digital presence

limula biotech financial estimates

Financial estimate

Revenue estimate

Valuation estimate

limula biotech leadership team

Management profile

Number of profiles

limula biotech funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

limula biotech M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about limula biotech

What does limula biotech do?

Limula Biotech develops and manufactures automated, all-in-one closed platforms for cell and gene therapy manufacturing. Its proprietary hardware combines a bioreactor and a centrifuge into a single device using in-situ centrifugation, enabling complex cell processing steps to be sequenced in one container without human intervention. The portfolio includes the LimONE automated closed manufacturing platform and the LimGROW scalable bioreactor for cell growth and expansion, sold to cell therapy developers, CDMOs, and pharmaceutical companies.

Is limula biotech a public or private company?

limula biotech is a private company. It is classified as venture growth investor backed and is currently operating.

When was limula biotech founded?

limula biotech was founded in 2020. It employs 11 to 50 people.

Where is limula biotech based?

limula biotech is headquartered in Epalinges, Switzerland, in the Europe region.

How does limula biotech make money?

Four revenue lines are on record. Hardware/Platform Sales are the primary driver. The others are consumables, software and partnership/Early Access Programs.

Who are limula biotech's main competitors?

Direct peers on record are Miltenyi Biotec, Cellares and Terumo BCT. Broad incumbents are Cytiva, Lonza, Sartorius, Thermo Fisher Scientific and Fresenius Kabi. Emerging players are Multiply Labs and Ori Biotech.

Does limula biotech have an API?

No public API is recorded for limula biotech.

What industry is limula biotech in?

limula biotech's product category is Cell Therapy Manufacturing Equipment. Its primary akta.pro industry code is HLAAABAG, Cell Therapy Manufacturing Platforms & Automation (closed systems, bioreactors, fill-finish), with a secondary code of HLAGAGAA, Cell Therapy CDMO (Autologous/Allogeneic Manufacturing). Its NAICS code is 3391 and its SIC code is 3841.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales